Bristol Myers Squibb expands US manufacturing footprint with US$2.3B Houston facility

USA—Bristol Myers Squibb (BMS) has selected Texas as the site for a new US$2.3 billion manufacturing facility, marking another major investment in US production as the Trump administration pushes pharmaceutical companies to expand domestic manufacturing.

The 600,000 ft² facility will be located at Generation Park in Houston and will manufacture medicines across BMS’ pipeline and portfolio.

Its capabilities will cover biologics, small molecules, and antibody-drug conjugates (ADCs), while its modular design will allow the company to adapt production areas as its needs change.

The facility will support the manufacture of drug products and finished goods for medicines in late-stage development and commercial production.

This flexibility will enable BMS to adjust its manufacturing capacity as products progress through development and reach the market.

Jobs and US investment

The digitally enabled site is expected to create nearly 500 skilled jobs once operational.

Construction and related activities will also generate approximately 2,000 jobs during the development of the facility.

The investment forms part of BMS’ broader US$ 40 billion commitment to strengthening its US operations, including its manufacturing and research and development (R&D) capabilities.

The company said the expansion will help increase its domestic capacity and support the development and production of medicines.

The project comes as the Trump administration increases pressure on pharmaceutical companies to manufacture more products in the US, including through the potential use of tariffs on imported medicines and pharmaceutical products.

For BMS, the Houston project also represents its first in-house manufacturing facility in Texas.

The company already has links to the state through a contract manufacturing partner that supports clinical and commercial production.

Texas attracts biopharma investment

Texas has increasingly positioned itself as a destination for biopharmaceutical R&D and manufacturing.

Texas Governor Greg Abbott attributed the state’s appeal to lower operating costs, access to US and international markets, and the availability of a skilled workforce.

BMS CEO Christopher Boerner similarly said Houston and Texas provide the talent, infrastructure, and partnerships required to support the development and production of new medicines.

BMS is also joining other major pharmaceutical companies expanding their presence in the state.

In September 2025, Eli Lilly committed US$6.5 billion to establish a manufacturing facility in Texas for its oral weight-loss medicine Foundayo (orforglipron).

Meanwhile, American biopharma companies have identified states including Virginia and North Carolina as emerging centres for pharmaceutical activity.

However, data from GlobalData’s Pharmaceutical Intelligence Center ranks Texas as the fifth most popular US state for biotech companies to establish operations.